Genotypic Analysis of Drug-Resistant HIV Cost-Effective

Article

WESTPORT, Conn-Genotypic analysis of drug-resistant HIV strains appears to be cost-effective.

A new study conducted by Milton C. Weinstein, MD, from the Harvard School of Public Health, used an HIV simulation model to incorporate data from several HIV-related trials to analyze the cost-effectiveness of genotypic resistance testing. HIV-infected subjects with baseline CD4 counts of 250 cells per microliter were the target group.

Researchers found that testing following antiretroviral failure increased life expectancy by 3 months and cost $17,900 per quality-adjusted-life-year (QALY) gained. The figure for primary resistance testing was $22,300 with 20% prevalence of primary resistance, but increased to $69,000 when prevalence was assumed to be only 4%.

The cost per QALY gained never exceeded $25,000 when effectiveness, multiple cost factors, quality-of-life weights, and discount rates were varied.

Information from www.hivandhepatitis.com

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
DJ Shannon, MPH, CIC, VA-BC, FAPIC
Jordan Bastian, MPH, CIC, at APIC25
Jordan Bastian, MPH, CIC, at APIC25
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Related Content